QR code

Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.

Shigellosis (bacillary dysentery) is a severe gastrointestinal infection with a global incidence of 90 million cases annually. Despite the severity of this disease, there is currently no licensed vaccine against shigellosis. Shigella’s primary virulence factor is its type III secretion system (T3SS)...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Ti Lu, Sayan Das, Debaki R. Howlader, Akshay Jain, Gang Hu, Zackary K. Dietz, Qi Zheng, Siva Sai Kumar Ratnakaram, Sean K. Whittier, David J. Varisco, Robert K. Ernst, William D. Picking, Wendy L. Picking
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2023-09-01
Reeks:Frontiers in Immunology
Onderwerpen:
Shigella
T3SS
IL-17
IFN-gamma
vaccine
Online toegang:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1194912/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items